Prior to joining atai, Galyna worked as a biopharma strategy consultant at Catenion. Her projects included R&D strategy development, competitive intelligence, multi-dimensional R&D project, technology, and indication valuation of 80+ assets among others. For over one year, Galyna fully focused on M&A activities, where she conducted process development, technology analyses, and due diligence in Neuroscience, Cardio-metabolic, Orphan, and Oncology areas.
She earned her Ph.D. in Neuroscience from EPFL in Lausanne, Switzerland, where she developed brain-controlled neuromodulation of the midbrain and spinal motor centers to enhance recovery after spinal cord injury. Prior to this, she was one of the top performers in an International Max Planck Research School in Tübingen, Germany, during her Master’s and researched neurophysiological mechanisms of perception and cognition in rats and carrion crows. She received her Bachelor’s degree in Physiology from the National University of Kyiv, Ukraine.